

Resource Summary Report

Generated by RRID on Jul 29, 2026

PE anti-mouse CD19

RRID:AB_2629816

Type: Antibody

Proper Citation

BioLegend Cat# 152407, RRID:AB_2629816

Antibody Information

URL: http://antibodyregistry.org/AB_2629816

Proper Citation: BioLegend Cat# 152407, RRID:AB_2629816

Target Antigen: CD19

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD19

Description: This monoclonal targets CD19

Target Organism: mouse

Clone ID: Clone 1D3/CD19

Antibody ID: AB_2629816

Vendor: BioLegend

Catalog Number: 152407

Alternative Catalog Numbers: 152408

Record Creation Time: 20250820T040415+0000

Record Last Update: 20250820T175726+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD19.

No alerts have been found for PE anti-mouse CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lee W, et al. (2025) Protocol for assessing mobilization of peritoneal B cells to the pre-metastatic omentum in an orthotopic mouse model of ovarian cancer. STAR protocols, 6(2), 103806.

Cao T, et al. (2024) Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T??cells. Cell, 187(9), 2288.

Haist KC, et al. (2024) A LTB4/CD11b self-amplifying loop drives pyogranuloma formation in chronic granulomatous disease. iScience, 27(4), 109589.

Gu X, et al. (2023) The midnolin-proteasome pathway catches proteins for ubiquitination-independent degradation. Science (New York, N.Y.), 381(6660), eadh5021.

Gungabeesoon J, et al. (2023) A neutrophil response linked to tumor control in immunotherapy. Cell, 186(7), 1448.

Tartey S, et al. (2021) A MyD88/IL1R Axis Regulates PD-1 Expression on Tumor-Associated Macrophages and Sustains Their Immunosuppressive Function in Melanoma. Cancer research, 81(9), 2358.